Skeletal Muscle Loss During Treatment With Abiraterone in Patients With Metastatic Prostate Cancer
Conclusions: SMI decline occurs during AAP treatment for mHSPC and mCRPC, and is more pronounced in patients over 75 years old and those without previous local treatment. There was no statistically significant association between survival outcomes and SMI decline during AAP therapy.
Kaydedildi:
| Asıl Yazarlar: | , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Wiley
2025-01-01
|
| Seri Bilgileri: | Prostate Cancer |
| Online Erişim: | http://dx.doi.org/10.1155/proc/1468262 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|